Semaglutide, tirzepatide and every GLP-1 peptide: a hard no at NoRamp
This is the most common reason an RUO peptide application is declined, and the most common reason a live merchant is terminated. Every GLP-1, GIP and incretin-class compound is a prescription drug. There is no Research Use Only version of a prescription drug for a storefront, and NoRamp does not process a single transaction for one.
What is covered
The prohibition covers the entire class, not a list of brand names. That includes, without limitation:
- Semaglutide, in any form, strength or presentation
- Tirzepatide, in any form, strength or presentation
- Retatrutide and other investigational multi-agonists
- Cagrilintide and amylin analogs marketed alongside the class
- Liraglutide, dulaglutide, exenatide and every other approved incretin-class drug
- Any analog, derivative, blend, coded product name, abbreviation or deliberate misspelling that refers to any of the above
It does not matter whether the compound is spelled out on a product page, abbreviated in a product code, hidden in a URL slug, drawn into an image, placed in alt text, or mentioned in a blog post. If it is on a domain connected to the merchant, the merchant is selling it as far as we are concerned.
Why the research label does not apply
Research Use Only is a regulatory status for reference materials that have no approved human use. An approved prescription drug is the opposite case: it has a defined, regulated chain from manufacturer to pharmacy to prescriber to patient, and selling it outside that chain is selling an unapproved or misbranded drug no matter what the label says.
The FDA has repeatedly warned consumers about GLP-1 products sold outside the regulated supply chain, and the card networks treat them as prohibited pharmaceuticals. A storefront that lists semaglutide as a research peptide is not operating in a gray area. It is operating in a clearly marked prohibited one, and so is any processor that takes its transactions.
What happens if we find it
- On an application: automatic decline, with no remediation path. We do not approve the rest of a catalog on the promise that these products will be removed.
- On a live merchant: same-day suspension and termination, funds held for as long as the networks permit, every card-network fine passed through in full, and a report to our processor, our banks, the networks and the FDA where appropriate.
Our nightly compliance scans look specifically for this class across every live merchant's public pages, and human reviewers check what the scans find. There is no setting that turns this off, and no merchant tier that is exempt.
If you sell GLP-1 compounds today
Do not apply to NoRamp. Removing the products the day before you apply does not change the history of the domain, and the application asks about it directly. Misrepresenting that history is itself an automatic decline and, for a live merchant, grounds for termination.
Frequently asked
Can I sell semaglutide as a Research Use Only peptide through NoRamp?
No. Semaglutide and every other GLP-1, GIP or incretin-class compound is a prescription drug. NoRamp does not process any transaction involving them, under any name, code or label, and a merchant found selling them is terminated the same day.
What if the GLP-1 products are on a separate domain from the one I apply with?
Undisclosed domains and mirror sites are an automatic decline, and for a live merchant they are grounds for same-day termination with fines passed through. We review every domain connected to the business, not just the one on the application.
Does NoRamp allow telehealth prescribing of GLP-1 medications?
That is a different category with its own rules. For licensed telehealth practices, see our telehealth industry page. For Research Use Only suppliers, the answer is no in every case.
Where we stand
NoRamp is the strictest payment processor in the world for Research Use Only. We are on the side of the card networks, the acquiring banks and the regulators, not on the side of a merchant who wants to see how close to the line they can operate. Approval is possible. It is rare, on purpose.